TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02173951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone
Description: in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deferiprone
Description: in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d
Study: NCT03149874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined hepatitis A and B vaccine
Description: Combined hepatitis A and B vaccine given to the patients
Study: NCT02537093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Consultation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric Consultation
Study: NCT04362566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: Scalp flap: 2.5cc salinefor 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to saline used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
Study: NCT02832063

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: 4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
Study: NCT02471820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
Study: NCT02286830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
Study: NCT04354974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation
Description: Evaluation of a cognitive remediation program for mood disorders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation
Description: Evaluation of a cognitive remediation program for mood disorders
Study: NCT04561063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/Daclatasvir
Description: Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
Study: NCT00900887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polietilenglicol 400, propilenglicol
Description: ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week
Study: NCT00664508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
Study: NCT03983148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer.
Study: NCT02439528

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis
Description: One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis
Description: One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis
Description: One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis
Description: One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.
Study: NCT04249726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct composite resin restoration
Description: A direct composite resin restoration will be provided intracoronally without cuspal coverage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite resin restoration followed by full coverage metal ceramic crown
Description: A direct composite resin restoration will be provided intracoronally followed by a full cuspal coverage metal ceramic crown.
Study: NCT02888418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
Description: Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
Description: Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
Description: Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02764424

Intervention type: DEVICE
Intervention: NIPE (MDoloris®)
Description: Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
Study: NCT00910143

Intervention type: PROCEDURE
Intervention: conventional rectal surgery
Description: type of rectal surgery before the introduction of TME

Intervention type: PROCEDURE
Intervention: total mesorectal excision
Description: total mesorectal excision
Study: NCT05055284

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.
Description: Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.
Description: Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
Study: NCT04090099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block
Description: While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block
Description: While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
Study: NCT00006103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT04444206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound cervical length screening
Description: Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
Study: NCT01454310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound coverage by acellular skin substitute
Description: Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous skin
Description: Matched burn wound is covered by autologous skin after tangential excision.
Study: NCT02286830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
Study: NCT01761227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fufangdanshen Tablets
Description: 1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 tablets per time, 3 times per day for 24 weeks
Study: NCT02762604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagined Gait Intervention
Description: Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Imagery Intervention
Description: Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
Study: NCT03568617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
Study: NCT04364438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Muscle Stimulation
Description: EMS is believed to produce some inhibition of the bladder, allowing the bladder to reach a greater volume. This is believed to occur because electrical stimulation also stimulates nerves in the pelvic floor. In most people, bladder voiding is inhibited when the skin of the pelvis is touched or otherwise manipulated. This inhibition is via a reflex in the spinal cord that may have evolved to inhibit voiding during sexual contact. The pelvic floor nerves are responsible for transmitting the sensation of touch from the pelvis to the spinal cord. Electrical stimulation of these nerves thus activates sensory fibers that cause inhibition of bladder voiding via a reflex mechanism in the spinal cord. This may explain EMS is an effective treatment for people with incontinence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: TENS is based on the gate control theory of abolishing the local micturition reflex arc. It is a non-pharmacological method of inhibiting the presynaptic afferent neurons carrying impulses from bladder by stimulating the nerves of peripheral segmental dermatome (gate control theory of electro modulation by stimulating the peripheral nerves corresponding to the visceral organ). It acts at the level of primitive voiding reflex coordinating the bladder, sphincter and the pelvic floor. Detrusor hyperreflexia can be inhibited by direct inhibition of impulses in the preganglionic afferent neuron or by inhibition of bladder preganglionic neurons of the efferent limb of micturition reflex.
Study: NCT03678714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity
Description: Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
Study: NCT01327183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: at least 1 hour and up to 24 hours after completion of drug infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: at least 1 hour and up to 24 hours after completion of drug infusion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)
Description: at least 1 hour and up to 24 hours after completion of drug infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study: NCT03793972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triage with referral to primary care
Description: During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
Study: NCT03853954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
Study: NCT02525211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion